FOLD · United States
Financials as of FY2025
Sells pills and drug combinations that stabilize broken proteins in patients with specific rare genetic diseases.
What this company is and how it runs — written from structure, not news.
Amicus Therapeutics sells drugs that physically stabilize misfolded proteins inside cells, and both its products work only in patients whose specific genetic mutation leaves enough protein structure intact for the drug to latch onto — so the drug's mechanism and the patient's eligibility test are the same molecular event. Because a confirmed genetic result is the only way to establish that a patient qualifies, the diagnostic infrastructure of variant-level genotyping is the commercial gatekeeper before any prescription can be written. The addressable population is therefore capped not by manufacturing capacity or sales reach but by however many patients with amenable mutations have actually been genotyped, a rate controlled by national testing coverage policies that Amicus cannot influence. The deepest risk to the whole structure is gene therapy: a treatment that permanently corrects the underlying GLA or GAA mutation would remove the misfolded protein entirely, and a drug whose entire purpose is to bind that misfolded protein would lose its target — and its patients — at the same time.
How does this company make money?
The company earns revenue each time a dose of Galafold is sold to a Fabry disease patient whose genetic variant has been confirmed as amenable. It also earns revenue from sales of the Pombiliti plus Opfolda combination to late-onset Pompe disease patients. Both products are priced within frameworks designed for ultra-rare disease drugs, and orphan drug exclusivity supports those prices by keeping generic competition off the market during the exclusivity period.
What makes this company hard to replace?
Switching is difficult because the entire basis for being on these drugs is a confirmed genetic test result. A patient would need to be re-evaluated and re-genotyped under a different diagnostic framework to move to an alternative therapy. Physicians also need specialized knowledge of which mutations make a patient eligible for chaperone treatment — that expertise is built around this specific approach and does not transfer cleanly to other treatment options.
What limits this company?
The number of eligible patients is fixed by how common the right genetic variants are within diseases that are already extremely rare. Building more factories or hiring more salespeople cannot create new patients. The only way to find more eligible patients is to test more undiagnosed people, and how often that happens depends on whether national health systems pay for genetic testing — something the company cannot control.
What does this company depend on?
The company cannot operate without FDA orphan drug designations for its Fabry and Pompe disease products. It also depends on genetic testing laboratories to identify which patients carry amenable mutations — without that diagnostic step, no prescriptions can flow. Specialized manufacturing facilities are required for both the small molecule chaperones and the recombinant enzyme cipaglucosidase alfa. Cold-chain distribution networks are needed to get enzyme therapies to patients without degradation. And ongoing EMA and FDA regulatory pathways for rare disease drugs govern whether products can stay on the market across different regions.
Who depends on this company?
Fabry disease patients with amenable genetic variants depend on the company for oral treatment. If the company stopped, those patients would have to return to intravenous enzyme replacement therapy, losing the option of a pill. Pompe disease treatment centers would lose the Pombiliti plus Opfolda combination and be left with older enzyme replacement therapies that deliver the enzyme to cells less effectively. Rare disease genetic testing laboratories that run mutation-specific screening tied to chaperone eligibility would also lose a significant source of demand.
How does this company scale?
The underlying pharmacological chaperone approach can be applied to other lysosomal storage diseases where proteins misfold in a similar way, so the scientific platform can support new pipeline drugs without rebuilding the R&D logic from scratch. What does not scale easily is manufacturing. Producing stable chaperone-enzyme combinations requires specialized facilities that must be individually validated by regulators, and the technical complexity of making these products means adding capacity takes significant time and investment.
What external forces can significantly affect this company?
Because both products serve fewer than 10,000 patients globally, their prices depend on health systems being willing to pay ultra-orphan drug rates — and reimbursement policies for drugs in this category can change. The rate at which new patients are identified depends on how broadly genetic testing is covered by different national health systems, which varies widely. International efforts to harmonize rare disease regulations across countries could either make it easier or harder to maintain approvals in multiple markets simultaneously.
Where is this company structurally vulnerable?
If a gene therapy permanently corrected the GLA mutation in Fabry disease or the GAA mutation in Pompe disease, it would fix the protein at the source. That would leave no misfolded protein for Galafold or the Opfolda chaperone to bind. Every patient successfully treated by such a gene therapy would no longer need these drugs at all, and orphan drug exclusivity offers no protection against a treatment that removes the underlying problem entirely.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph